List view / Grid view
Final Phase 2 PALOMA-1 data to be presented for potential…
7 April 2014 | By Pfizer
Final Phase 2 PALOMA-1 data to be presented for potential first-in-class palbociclib...
Agreement to combine Merck’s investigational anti-PD-1 and key Pfizer oncology…
5 February 2014 | By Pfizer
Agreement to combine Merck’s investigational anti-PD-1 and key Pfizer oncology assets...
Clinical benefit demonstrated for potential first-in-class CDK 4 and 6…
3 February 2014 | By Pfizer
Clinical benefit demonstrated for potential first-in-class CDK 4 and 6 inhibitor...
An Ongoing, Third Phase 3 Trial is Evaluating Dacomitinib in…
27 January 2014 | By Pfizer
An Ongoing, Third Phase 3 Trial is Evaluating Dacomitinib in First-Line in EGFR-Mutant NSCLC...
